SpringWorks Therapeutics (SWTX)
(Real Time Quote from BATS)
$33.92 USD
-0.46 (-1.34%)
Updated Sep 23, 2024 09:46 AM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for SpringWorks Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -325.10 | -277.42 | -173.91 | -45.57 | -58.31 |
Depreciation/Amortization & Depletion | 1.67 | 0.77 | 0.49 | 0.35 | 0.19 |
Net Change from Assets/Liabilities | -0.58 | 38.10 | 5.12 | 1.35 | 4.95 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 101.23 | 76.99 | 40.43 | 11.69 | 5.72 |
Net Cash From Operating Activities | -222.80 | -161.56 | -127.88 | -32.19 | -47.44 |
Property & Equipment | -7.39 | -10.20 | -2.02 | -0.64 | -0.67 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 42.14 | -205.40 | 85.61 | -418.19 | -3.59 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 34.75 | -215.60 | 83.59 | -418.83 | -4.26 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -2.66 | 56.09 | 1.16 | 0.89 | 0.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 299.30 | 284.61 | 0.00 | 269.59 | 333.69 |
Net Cash from Financing Activities | 296.64 | 340.70 | 1.16 | 270.49 | 333.71 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 108.60 | -36.46 | -43.13 | -180.54 | 282.00 |
Cash at Beginning of Period | 68.07 | 104.53 | 147.65 | 328.19 | 46.19 |
Cash at End of Period | 176.67 | 68.07 | 104.53 | 147.65 | 328.19 |
Diluted Net EPS | -5.15 | -5.21 | -3.59 | -1.05 | -3.81 |
Fiscal Year End for SpringWorks Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -127.30 | -87.39 | -325.10 | -230.78 | -151.35 |
Depreciation/Amortization & Depletion | 1.57 | 0.73 | 1.67 | 1.13 | 0.64 |
Net Change from Assets/Liabilities | -55.34 | -24.16 | -0.58 | -4.28 | -8.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 60.35 | 31.89 | 101.23 | 73.85 | 49.29 |
Net Cash From Operating Activities | -120.72 | -78.93 | -222.80 | -160.09 | -109.63 |
Property & Equipment | -1.55 | -0.58 | -7.39 | -9.69 | -6.07 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 34.55 | 22.04 | 42.14 | 203.65 | 165.43 |
Other Investing Activities | -11.25 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 21.75 | 21.46 | 34.75 | 193.96 | 159.36 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.82 | -0.55 | -2.66 | -2.43 | -2.19 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 299.30 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.82 | -0.55 | 296.64 | -2.43 | -2.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -96.15 | -58.02 | 108.60 | 31.44 | 47.54 |
Cash at Beginning of Period | 176.67 | 176.67 | 68.07 | 68.07 | 68.07 |
Cash at End of Period | 80.52 | 118.65 | 176.67 | 99.51 | 115.61 |
Diluted Net EPS | -0.54 | -1.18 | -1.45 | -1.27 | -1.25 |